• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腺瘤:治疗结果及放射治疗的作用

Thymoma: Results of treatment and role of radiotherapy.

作者信息

Hetnał Marcin, Małecki Krzysztof, Wolanin Magdalena, Korzeniowski Stanisław, Walasek Tomasz

机构信息

Radiation Oncology Department, Centre of Oncology, Krakow, Poland.

Brain, Head and Neck Cancer Unit, Centre of Oncology, Krakow, Poland.

出版信息

Rep Pract Oncol Radiother. 2010 Feb 18;15(1):15-20. doi: 10.1016/j.rpor.2010.01.004. eCollection 2010.

DOI:10.1016/j.rpor.2010.01.004
PMID:24376917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3863136/
Abstract

PURPOSE

The aim of this study is to assess results of treatment, factors influencing prognosis with regard to causes of failure and treatment tolerance in patients with thymoma.

MATERIAL AND METHODS

Between 1966 and 2006, 63 patients with thymoma had been treated at the Centre of Oncology in Krakow. Patients were treated by means of different treatment modalities: surgery followed by radiotherapy (52%), radiotherapy alone (13%), chemoradiotherapy alone (15%), surgery followed by chemoradiotherapy (5%), surgery alone (5%) and others.

RESULTS

The 10-year locoregional recurrence-free survival (LRRFS) was 79%, disease free survival (DFS) was 57% and overall survival (OS) was 57%. Masaoka stage was the only independent prognostic factor for LRRFS. Masaoka stage and method of radiotherapy delivery (higher photon energies), were independent prognostic factors for OS. For DFS, the independent prognostic factors were age, type of treatment (favoured surgery followed by radiotherapy or chemoradiotherapy), Masaoka stage and year of start of treatment. Most common reactions were lung fibrosis in 36% of patients (mainly asymptomatic in most patients), pneumonitis (9%) and oesophagitis (4%).

CONCLUSIONS

Surgery combined with radiotherapy and chemoradiotherapy and modern radiotherapy techniques are correlated with improvement of survival in patients with early stage thymoma.

摘要

目的

本研究旨在评估胸腺瘤患者的治疗结果、影响预后的因素,包括失败原因和治疗耐受性。

材料与方法

1966年至2006年间,克拉科夫肿瘤中心共治疗了63例胸腺瘤患者。患者接受了不同的治疗方式:手术加放疗(52%)、单纯放疗(13%)、单纯放化疗(15%)、手术加放化疗(5%)、单纯手术(5%)及其他治疗。

结果

10年局部区域无复发生存率(LRRFS)为79%,无病生存率(DFS)为57%,总生存率(OS)为57%。Masaoka分期是LRRFS的唯一独立预后因素。Masaoka分期和放疗方式(较高光子能量)是OS的独立预后因素。对于DFS,独立预后因素为年龄、治疗类型(倾向于手术加放疗或放化疗)、Masaoka分期和治疗开始年份。最常见的反应是36%的患者出现肺纤维化(大多数患者主要无症状)、肺炎(9%)和食管炎(4%)。

结论

手术联合放疗、化疗以及现代放疗技术与早期胸腺瘤患者生存率的提高相关。

相似文献

1
Thymoma: Results of treatment and role of radiotherapy.胸腺瘤:治疗结果及放射治疗的作用
Rep Pract Oncol Radiother. 2010 Feb 18;15(1):15-20. doi: 10.1016/j.rpor.2010.01.004. eCollection 2010.
2
Tracheal cancer: Role of radiation therapy.气管癌:放射治疗的作用
Rep Pract Oncol Radiother. 2010 Oct 6;15(5):113-8. doi: 10.1016/j.rpor.2010.08.005. eCollection 2010.
3
Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study.化疗联合放疗对比手术联合术后放疗治疗扁桃体癌:韩国放射肿瘤学会研究
BMC Cancer. 2017 Aug 30;17(1):598. doi: 10.1186/s12885-017-3571-3.
4
Thymoma: inter-relationships among World Health Organization histology, Masaoka staging and myasthenia gravis and their independent prognostic significance: a single-centre experience.胸腺瘤:世界卫生组织组织学分型、Masaoka 分期、重症肌无力之间的相互关系及其独立的预后意义:单中心经验。
Eur J Cardiothorac Surg. 2011 Jul;40(1):146-53. doi: 10.1016/j.ejcts.2010.09.042. Epub 2010 Nov 18.
5
Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study.III期胸腺瘤:手术及术后放疗后的失败模式及其对未来研究的启示
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):927-33. doi: 10.1016/s0360-3016(99)00514-3.
6
Long-term outcomes of 307 patients after complete thymoma resection.307例胸腺瘤完全切除术后的长期预后
Chin J Cancer. 2017 May 15;36(1):46. doi: 10.1186/s40880-017-0213-8.
7
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience.治疗复发性胸腺瘤后预后因素:一项多中心经验。
Lung Cancer. 2019 Dec;138:27-34. doi: 10.1016/j.lungcan.2019.09.024. Epub 2019 Sep 30.
8
Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma.局部晚期 Masaoka-Koga 分期 III 胸腺瘤根治性放疗与肿瘤减灭术对治疗结局和预后的影响。
Sci Rep. 2020 Feb 3;10(1):1735. doi: 10.1038/s41598-020-58692-2.
9
[Role of Postoperative Radiotherapy for Stage I/II/III Thymic Tumor - Results of the ChART Retrospective Database].[术后放疗对Ⅰ/Ⅱ/Ⅲ期胸腺瘤的作用——ChART回顾性数据库结果]
Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):465-72. doi: 10.3779/j.issn.1009-3419.2016.07.09.
10
Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution.完全切除的Masaoka III期胸腺瘤术后放疗:单机构65例回顾性研究
Radiat Oncol. 2013 Aug 13;8:199. doi: 10.1186/1748-717X-8-199.

引用本文的文献

1
Thymoma-associated T-cell immunodeficiency after radiotherapy: A case report.放疗后胸腺瘤相关T细胞免疫缺陷:一例报告
Respir Med Case Rep. 2021 Apr 2;33:101408. doi: 10.1016/j.rmcr.2021.101408. eCollection 2021.
2
Thymoma-associated Myasthenia Gravis in a Young Adult with Development of Paraneoplastic Limbic Encephalitis and Systemic Lupus Erythematosus Post-thymectomy: A Case Report.一名青年成年患者的胸腺瘤相关性重症肌无力,胸腺切除术后并发副肿瘤性边缘叶脑炎和系统性红斑狼疮:病例报告
Cureus. 2018 Nov 13;10(11):e3581. doi: 10.7759/cureus.3581.
3
Entire hemithorax irradiation for Masaoka stage IVa thymomas.对Masaoka Ⅳa期胸腺瘤进行全半胸照射。
Rep Pract Oncol Radiother. 2012 Jul 15;17(6):384-8. doi: 10.1016/j.rpor.2012.05.004. eCollection 2012.

本文引用的文献

1
A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features.一个机构10多年来手术切除胸腺上皮肿瘤的经验:临床结果和临床病理特征
Oncol Rep. 2008 Jun;19(6):1525-31.
2
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection.胸腺上皮肿瘤的新型预后分组:风险评估与治疗策略选择
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):420-7. doi: 10.1016/j.ijrobp.2007.10.006. Epub 2007 Dec 31.
3
Malignant thymomas--the experience of the Portuguese Oncological Institute, Porto, and literature review.恶性胸腺瘤——葡萄牙波尔图肿瘤研究所的经验及文献综述
Rev Port Pneumol. 2007 Jul-Aug;13(4):553-85.
4
Thymoma needs a new staging system.胸腺瘤需要一个新的分期系统。
Interact Cardiovasc Thorac Surg. 2004 Mar;3(1):163-7. doi: 10.1016/S1569-9293(03)00265-2.
5
Role of chemotherapy in the management of advanced thymic tumors.化疗在晚期胸腺瘤治疗中的作用。
Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):41-50. doi: 10.1053/j.semtcvs.2004.11.003.
6
Radiation therapy in the management of thymic tumors.胸腺肿瘤治疗中的放射疗法。
Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):32-40. doi: 10.1053/j.semtcvs.2004.12.005.
7
Treatment of malignant thymoma.恶性胸腺瘤的治疗
Curr Opin Oncol. 2005 Mar;17(2):140-6. doi: 10.1097/01.cco.0000152628.43867.8e.
8
Multimodality treatment program in invasive thymic epithelial tumor.侵袭性胸腺上皮肿瘤的多模态治疗方案
Am J Clin Oncol. 2005 Feb;28(1):5-7. doi: 10.1097/01.coc.0000138963.01562.d3.
9
Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients.胸腺瘤的放疗与预后因素:175例患者的回顾性研究
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1113-9. doi: 10.1016/j.ijrobp.2004.05.013.
10
Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification.根据世界卫生组织新的组织学分类对胸腺上皮肿瘤的预后评估
Ann Thorac Surg. 2004 Sep;78(3):992-7; discussion 997-8. doi: 10.1016/j.athoracsur.2004.03.097.